ZBIO Earnings & Financial Statements
Zenas BioPharma, Inc.
$28.18
+$1.24(+4.60%)
46
Overall
45
Value
54
Tech
39
Quality
Market Cap
$1.76B
Volume
509.12K
52W Range
$13.50 - $44.60
Target Price
$47.88
ZBIO earnings and financial statements: Zenas BioPharma, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ZBIO Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $10.00M | $5.00M | $50.00M |
| Cost of revenue | $171.67M | - | - |
| Operating income | -$383.06M | -$163.89M | -$37.15M |
| EBITDA | -$372.33M | -$163.75M | -$36.71M |
| Net income | -$377.70M | -$156.99M | -$37.12M |
| EPS (diluted) | $-8.44 | $-11.89 | - |
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Total assets | $383.64M | $369.97M | $68.18M |
| Total liabilities | $141.50M | $57.51M | $43.81M |
| Shareholders’ equity | $242.14M | $312.46M | $24.36M |
| Cash and equivalents | $110.64M | $319.74M | $56.86M |
| Long-term debt | $78.85M | $218.0K | $257.0K |
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating cash flow | -$172.33M | -$119.67M | -$30.53M |
| Capital expenditure | -$18.0K | -$131.0K | - |
| Free cash flow | -$172.35M | -$119.81M | -$30.55M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ZBIO | $28.18 | +4.6% | 509.12K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |